51.

The following statements regarding alpha adrenergic antagonists are TRUE;

except
A. decreases sympathetic outflow
B. alpha antagonist decreases resistance to urinary outflow
. !loc"ade of alpha#$ receptors facilitates insulin release
%. alpha#1 antagonist causes fall in mean arterial !lood pressure
E. none of the a!o&e
5$. '(irst dose phenomenon) is associated with
A. *hentolamine
B. *ra+osin
. Tola+oline
%. *henoxy!en+amine
E. none of the a!o&e
5,. All of the following statements concerning adrenergic receptors are
-RRET; except
A. acti&ation of the presynaptic alpha$#receptors inhi!it the release of
neurotransmitter
B. phentolamine is an adrenergic receptor antagonist
. isoproterenol is ineffecti&e agonist in alpha$#adrenergic receptors
%. the most potent adrenergic receptor agonist is norepinephrine
E. none of the a!o&e
5.. The following statements are TRUE regarding cholinergic receptors;
E/E*T
A. the receptor antagonist is muscarine
B. nicotinic receptors are found in striated muscles
. hexamethonium !loc"s ganglionic nicotinic receptors
%. muscarinic receptors may found in the 01
E. none of the a!o&e
55. The most potent agonist in !eta1 adrenergic receptors is
A. epinephrine
B. norepinephrine
. isoproterenol
%. propranolol
E. none of the a!o&e
52. Actions of the -piate at Mu receptor are the following E/E*T
A. increased 34 motility
B. *upillary constriction
. Euphoria
%. 1edation
E. A 5 B only
56. 7hich of the following is 0-T an action of -piates at Sigma receptor8
A. pupillary constriction
B. analgesia
. euphoria
%. decreased 34 motility
E. All of the a!o&e
59. The following are strong agonists on opiate receptors; E/E*T
A. :orphine
B. odeine
. :eperidine
%. :ethadone
E. 0one of the A!o&e
5;. The following are pharmacologic effects of :orphine; E/E*T
A. !ronchodilation
B. increased detrusor muscle tone
. cutaneous &asodilation
%. constipation
E. 0one of the a!o&e
2<. Toxic effects of :orphine; E/E*T
A. respiratory depression
B. se&ere diarrhea
. miosis
%. delayed gastric emptying time
E. none of the a!o&e
21. 4t satisfies cra&ing for heroin without euphoria or somnolence
A. :eperidine
B. :ethadone
. :orphine
%. 0aloxone
E. Any of the a!o&e
2$. The following statements are associated with codeine; E/E*T
A. analgesic effect is e=uipotent with aspirin
B. pharmacologic effects is similar to morphine
C. cough suppressant
%. 1>1$ the analgesic potency of morphine
E. 0one of the a!o&e

Matching Type II
Activation of the following Receptor Type
A. alpha
B. !eta 1
. !eta $
%. :1
E. :$
End-organ Effects
????? 2,. :ydriasis
????? 2.. relaxation of the !ronchi
????? 25. &asodilation
????? 22. increased inotropism
????? 26. coronary constriction
29. 4t is the treatment of choice for patients addicted to -pioids and heroin
A. 0al!uphine
B. :ethadone
. 0aloxone
%. 0altrexone
E. All of the a!o&e
2;. Beta $ receptors are normally found in
A. smooth muscles
B. cardiac muscles
. lipocytes
%. A 5 B only
E. all of the a!o&e
6<. 4t is used as prophylactic agent for migraine attac"
A. :ethylsergide
B. *ropranolol
. Ergotamine tartrate
%. A and B only
E. A and only
61. Anticholinergic drugs are used for the following indications; E/E*T
A. Antidepressants
B. Antipsychotic
. Antihistamines
%. Antispasmodic
E. 0one of the a!o&e
6$. 7hich anticholinergic agent is rapidly and fully distri!uted in the 018
A. Atropine
B. 4patropium
. 1copolamine
%. @omatropine
E. All of the a!o&e
6,. The following are pharmacologic effects of antimuscarinic agents; E/E*T
A. cycloplegia
B. reduces rigidity in *ar"insonAs disease
. mydriasis
%. !ronchodilation
E. none of the a!o&e
6.. 7hich tissue>tissues is>are most sensiti&e to Atropine8
A. heart
B. sali&ary glands
. smooth muscles
%. sweat glands
E. B 5 % only
65. 7hich agent is used as an antidote for organophosphate poisoning8
A. 1copolamine
B. 4patropium
. Atropine
%. @yoscine
E. Any of the a!o&e
62. The following are effects of Atropine; E/E*T
A. dry mouth
B. hyperacidity
. !ronchodilation
%. prolonged gastric emptying time
E. none of the a!o&e
66. The following statements are TRUE regarding 0aloxone; E/E*T
A. contraindicated in patients with Acute hepatitis
B. 0o tolerance will occur at therapeutic dose
. full antagonist to opiate receptors
%. antagonistic effects usually lasts in 1#. hours
E. none of the a!o&e
69. 7hich agent is widely used in the treatment of !ronchial asthma8
A. 1copolamine
B. Atropine
. @yoscine 0# Butyl Bromide
%. 4patropium
E. 0one of the a!o&e
6;. The following are associated with Antimuscarinic agents; E/E*T
A. contraindicated in constipation
B. relaxation of the uterus
. increased intestinal transit time
%. an antidepressant
E. none of the a!o&e
9<. 7hich anticholinergic agents ha&e the longest duration of effects on the
eyes8
A. tropicamide
B. cyclopentolate
. scopolamine
%. atropine
E. all of the a!o&e
91. *harmacologic effects of Beta#adrenergic !loc"ers; E/E*T
A. Beta#1 !loc"ade increases airway resistance
B. decreases total coronary !lood flow and oxygen consumption
. reduces !lood flow in the !rain
%. prolong systole
E. A and only
9$. %oxa+osin is characteri+ed as
A. 0on#selecti&e 4rre&ersi!le alpha !loc"er
B. 0on#selecti&e re&ersi!le alpha !loc"er
. Alpha1#selecti&e alpha !loc"er
%. Alpha $#selecti&e alpha !loc"er
E. A 5 only
9,. All of the following statements regarding Alpha !loc"ing agents are TRUE;
except
A. antihypertensi&e agents
B. their effects can !e surmounted !y increased concentration of agonists
. 0onselecti&e !loc"ers has no significant direct cardiac effects
%. reduction in &ascular tone with a reduction of !oth arterial and &enous
pressure is the most important effects of nonselecti&e alpha !loc"ing
agents
E. 0one of the a!o&e
9.. *harmacologic effects of ergot al"aloids; E/E*T
A. directly stimulate smooth muscles
B. can cause anxiety
. significant ele&ation of B*
%. &asodilation
E. none of the a!o&e
95. 7hich of the following agents decreases postpartum !leeding8
A. methylergono&ine maleate
B. ergotamine tartrate
. ergono&ine maleate
%. methylsergide
E. A 5 only
92. 4t is used as prophylactic agent for migraine attac"s
A. Ergotamine tartrate
B. :ethylsergide
. *ra+osin
%. A 5 B only
E. none of the a!o&e
96. Ergot al"aloids should not !e gi&en in patients with
A. anemia
B. arrhythmias
. hypertension
%. !ronchial asthma
E. All of the a!o&e
99. 4t is a powerful oxytocic agent
A. :ethylergono&ine maleate
B. Ergotamine tartrate
. Ergono&ine maleate
%. :ethylsergide
E. A 5 only
9;. An agent used to control autonomic hyperreflexia
A. *hentolamine
B. *ra+osin
. *henoxy!en+amine
%. Tola+oline
E. 0one of the a!o&e
;<. 7hich alpha !loc"er is indicated in the treatment of *ersistent *ulmonary
@ypertension in children8
A. *hentolamine
B. Tola+oline
. Both
%. 0either
Matching Type III
A. lassification
A. B1#receptor selecti&e
B. B$#receptor selecti&e
. 0on#selecti&e !eta !loc"er
%. Alpha 5 !eta !loc"er
?????;1. timolol
?????;$. car&edilol
?????;,. atenolol
?????;.. propranolol
;5. *harmacologic effects of *ropranolol; E/E*T
A. decreases total coronary !lood flow and oxygen consumption
B. decreases cardiac output and coronary oxygen consumption
. reduces !lood flow in most tissues
%. &asodilation
E. none of the a!o&e
;2. Beta !loc"ers causes !ronchoconstriction; E/E*T
A. :etoprolol
B. *ropranolol
. Aceta!ulol
%. Atenolol
E. none of the a!o&e
;6. Therapeutic effects of *ropranolol; E/E*T
A. prophylaxis of angina pectoris
B. reduces force of myocardial contraction
. decrease heart rate in hyperthyrotoxicosis
%. prophylaxis in migraine attac"s
E. none of the a!o&e
;9. 4t is a potent !eta !loc"er indicated in lowering of 4-*
A. :etoprolol
B. Timolol
. Betaxolol
%. 1otalol
E. 0one of the a!o&e
;;. The following are non#selecti&e !eta !loc"ers; E/E*T
A. 1otalol
B. Timolol
. Ba!etalol
%. *indolol
E. none of the a!o&e
1<<. 4t is a topical agent in the treatment of glaucoma
A. timolol
B. !etaxolol
. aceta!ulol
%. metoprolol
E. 0one of the a!o&e